AUTSX2
MCID: ATS366
MIFTS: 44

Autism X-Linked 2 (AUTSX2)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Autism X-Linked 2

MalaCards integrated aliases for Autism X-Linked 2:

Name: Autism X-Linked 2 58
Mental Retardation, X-Linked 58 13 41 74
Autism, Susceptibility to, X-Linked 2 58 30 6
X-Linked Mental Retardation 77 38
Autsx2 58 76
Autism Susceptibility, X-Linked 2 58
Mental Retardation, X-Linked ) 41
Autism, X-Linked 2 76

Characteristics:

OMIM:

58
Inheritance:
isolated cases
multifactorial
x-linked

Miscellaneous:
genetic heterogeneity (see )
onset by 3 years of age
male to female ratio 4:1
occurs in 2-5 per 10,000 individuals
associated with tuberous sclerosis
associated with untreated phenylketonuria


HPO:

33
autism x-linked 2:
Onset and clinical course childhood onset
Inheritance heterogeneous x-linked inheritance multifactorial inheritance sporadic


Classifications:



Summaries for Autism X-Linked 2

OMIM : 58 Autism, the prototypic pervasive developmental disorder (PDD), is usually apparent by 3 years of age. It is characterized by a triad of limited or absent verbal communication, a lack of reciprocal social interaction or responsiveness, and restricted, stereotypic, and ritualized patterns of interests and behavior (Bailey et al., 1996; Risch et al., 1999). 'Autism spectrum disorder,' sometimes referred to as ASD, is a broader phenotype encompassing the less severe disorders Asperger syndrome (see ASPG1; 608638) and pervasive developmental disorder, not otherwise specified (PDD-NOS). 'Broad autism phenotype' includes individuals with some symptoms of autism, but who do not meet the full criteria for autism or other disorders. Mental retardation coexists in approximately two-thirds of individuals with ASD, except for Asperger syndrome, in which mental retardation is conspicuously absent (Jones et al., 2008). Genetic studies in autism often include family members with these less stringent diagnoses (Schellenberg et al., 2006). For a discussion of genetic heterogeneity of autism, see 209850. (300495)

MalaCards based summary : Autism X-Linked 2, also known as mental retardation, x-linked, is related to mental retardation, x-linked, with or without seizures, arx-related and mental retardation, x-linked, syndromic, turner type. An important gene associated with Autism X-Linked 2 is NLGN4X (Neuroligin 4 X-Linked), and among its related pathways/superpathways is Regulation of actin cytoskeleton. The drugs Lovastatin and Riluzole have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and testes, and related phenotypes are seizures and eeg abnormality

UniProtKB/Swiss-Prot : 76 Autism, X-linked 2: A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate mental retardation.

Wikipedia : 77 X-linked intellectual disability (previously known as X-linked mental retardation) refers to forms of... more...

Related Diseases for Autism X-Linked 2

Diseases in the Autism X-Linked 2 family:

Autism X-Linked 1 Autism X-Linked 3
Autism X-Linked 4 Autism X-Linked 5
Autism X-Linked 6

Diseases related to Autism X-Linked 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 163, show less)
# Related Disease Score Top Affiliating Genes
1 mental retardation, x-linked, with or without seizures, arx-related 12.9
2 mental retardation, x-linked, syndromic, turner type 12.8
3 mental retardation, x-linked, syndromic 13 12.8
4 mental retardation, x-linked, syndromic, cabezas type 12.8
5 mental retardation, x-linked, with cerebellar hypoplasia and distinctive facial appearance 12.7
6 mental retardation, x-linked 12 12.7
7 mental retardation, x-linked, with panhypopituitarism 12.7
8 mental retardation, x-linked, syndromic, nascimento type 12.7
9 mental retardation, x-linked, syndromic, hedera type 12.7
10 mental retardation, x-linked, syndromic, claes-jensen type 12.7
11 mental retardation, x-linked, syndromic, wu type 12.7
12 mental retardation, x-linked, syndromic, raymond type 12.7
13 mental retardation, x-linked 97 12.7
14 mental retardation, x-linked, syndromic 32 12.7
15 mental retardation, x-linked, syndromic 34 12.7
16 mental retardation, x-linked, syndromic, martin-probst type 12.7
17 mental retardation, x-linked 96 12.7
18 mental retardation, x-linked, associated with fragile site fraxe 12.7
19 mental retardation, x-linked 21 12.7
20 mental retardation, x-linked, syndromic, christianson type 12.7
21 mental retardation, x-linked 98 12.7
22 mental retardation, x-linked 99 12.7
23 mental retardation, x-linked 100 12.7
24 mental retardation, x-linked 101 12.7
25 mental retardation, x-linked 92 12.7
26 mental retardation, x-linked 102 12.7
27 mental retardation, x-linked, syndromic 33 12.7
28 mental retardation, x-linked, syndromic, 35 12.7
29 mental retardation, x-linked 99, syndromic, female-restricted 12.6
30 mental retardation, x-linked 103 12.6
31 mental retardation, x-linked 104 12.6
32 mental retardation, x-linked 105 12.6
33 mental retardation, x-linked, syndromic, bain type 12.6
34 mental retardation, x-linked 106 12.6
35 mental retardation, x-linked, syndromic, houge type 12.6
36 mental retardation, x-linked 107 12.6
37 mental retardation, x-linked, syndromic 17 12.5
38 mental retardation, x-linked, syndromic, chudley-schwartz type 12.5
39 mental retardation, x-linked, syndromic, snyder-robinson type 12.5
40 mental retardation, x-linked, syndromic 9 12.4
41 mental retardation, x-linked 23 12.4
42 mental retardation, x-linked 50 12.4
43 mental retardation, x-linked 53 12.4
44 mental retardation, x-linked 42 12.4
45 mental retardation, x-linked, with craniofacial dysmorphism 12.4
46 mental retardation, x-linked 73 12.4
47 syndromic x-linked mental retardation hough type 12.3
48 pettigrew syndrome 12.3
49 lubs x-linked mental retardation syndrome 12.2
50 wilson-turner x-linked mental retardation syndrome 12.2
51 raynaud-claes syndrome 12.2
52 chromosome xp11.22 duplication syndrome 12.2
53 methylmalonic acidemia and homocysteinemia, cblx type 12.1
54 mental retardation and microcephaly with pontine and cerebellar hypoplasia 12.1
55 tonne-kalscheuer syndrome 12.1
56 stocco dos santos x-linked mental retardation syndrome 12.0
57 corpus callosum, agenesis of, with mental retardation, ocular coloboma, and micrognathia 12.0
58 mental retardation-hypotonic facies syndrome, x-linked, 1 12.0
59 cerebral creatine deficiency syndrome 1 11.9
60 renpenning syndrome 1 11.9
61 rolandic epilepsy, mental retardation, and speech dyspraxia, x-linked 11.9
62 mehmo syndrome 11.8
63 lujan-fryns syndrome 11.8
64 coffin-lowry syndrome 11.7
65 non-syndromic x-linked intellectual disability 11.7
66 partington x-linked mental retardation syndrome 11.7
67 wieacker-wolff syndrome 11.7
68 syndromic x-linked intellectual disability siderius type 11.7
69 fragile x syndrome 11.6
70 arts syndrome 11.6
71 prieto x-linked mental retardation syndrome 11.6
72 christianson syndrome 11.6
73 abidi x-linked mental retardation syndrome 11.6
74 syndromic x-linked intellectual disability snyder type 11.6
75 syndromic x-linked intellectual disability cabezas type 11.6
76 hsd10 mitochondrial disease 11.5
77 allan-herndon-dudley syndrome 11.5
78 ck syndrome 11.5
79 borjeson-forssman-lehmann syndrome 11.5
80 syndromic x-linked intellectual disability turner type 11.5
81 miles-carpenter syndrome 11.5
82 corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome 11.5
83 syndromic x-linked intellectual disability raymond type 11.5
84 syndromic x-linked intellectual disability shashi type 11.5
85 alpha thalassemia-x-linked intellectual disability syndrome 11.5
86 dandy-walker malformation with intellectual disability, basal ganglia disease and seizures 11.5
87 x-linked intellectual disability-plagiocephaly syndrome 11.5
88 armfield x-linked mental retardation syndrome 11.3
89 chromosome xp11.3 deletion syndrome 11.3
90 intellectual developmental disorder, x-linked 108 11.3
91 alpha-thalassemia/mental retardation syndrome, x-linked 11.3
92 mental retardation with optic atrophy, deafness, and seizures 11.3
93 russell-silver syndrome, x-linked 11.3
94 schimke x-linked mental retardation syndrome 11.3
95 syndromic x-linked intellectual disability 7 11.3
96 syndromic x-linked intellectual disability type 10 11.3
97 syndromic x-linked intellectual disability abidi type 11.3
98 syndromic x-linked intellectual disability nascimento type 11.3
99 lujan syndrome 11.3
100 severe x-linked intellectual disability, gustavson type 11.3
101 tranebjaerg svejgaard syndrome 11.3
102 x-linked intellectual disability, abidi type 11.3
103 x-linked intellectual disability, schimke type 11.3
104 x-linked intellectual disability, siderius type 11.3
105 encephalopathy, neonatal severe, due to mecp2 mutations 11.3
106 mental retardation smith fineman myers type 11.3
107 renier gabreels jasper syndrome 11.3
108 epileptic encephalopathy, early infantile, 1 10.5
109 microcephaly 10.5
110 epilepsy 10.4
111 hypotonia 10.3
112 cleft palate, isolated 10.3
113 autism 10.3
114 craniosynostosis with fibular aplasia 10.3
115 alpha-thalassemia 10.3
116 thalassemia 10.3
117 hypogonadism 10.3
118 hypogonadotropism 10.3
119 cleft lip 10.3
120 growth hormone deficiency 10.3
121 angelman syndrome 10.2
122 cerebellar hypoplasia 10.2
123 rett syndrome 10.2
124 west syndrome 10.2
125 hydrocephalus 10.2
126 aphasia 10.2
127 isolated growth hormone deficiency 10.2
128 stocco dos santos syndrome 10.2
129 tremor 10.2
130 alzheimer disease 10.0
131 huntington disease 10.0
132 osteoporosis 10.0
133 chromosome 2q35 duplication syndrome 10.0
134 corpus callosum, agenesis of 10.0
135 cryptorchidism, unilateral or bilateral 10.0
136 fryns syndrome 10.0
137 epileptic encephalopathy, early infantile, 8 10.0
138 opitz-kaveggia syndrome 10.0
139 pelizaeus-merzbacher disease 10.0
140 retinal dysplasia, primary 10.0
141 brown syndrome 10.0
142 bipolar disorder 10.0
143 periventricular nodular heterotopia 10.0
144 brachydactyly 10.0
145 autism spectrum disorder 10.0
146 syndromic x-linked intellectual disability 14 10.0
147 ichthyosis 10.0
148 agammaglobulinemia 10.0
149 tic disorder 10.0
150 infertility 10.0
151 paraplegia 10.0
152 basal ganglia disease 10.0
153 muscular atrophy 10.0
154 achalasia 10.0
155 nsdhl-related disorders 10.0
156 2-methyl-3-hydroxybutyric aciduria 10.0
157 bullous dystrophy hereditary macular type 10.0
158 dandy-walker complex 10.0
159 intellectual disability-developmental delay-contractures syndrome 10.0
160 spasticity 10.0
161 developmental dyspraxia 10.0
162 cleft lip/palate 10.0
163 perrault syndrome 1 8.7 MRX23 MRX42 MRX50 MRX53 MRX73

Graphical network of the top 20 diseases related to Autism X-Linked 2:



Diseases related to Autism X-Linked 2

Symptoms & Phenotypes for Autism X-Linked 2

Human phenotypes related to Autism X-Linked 2:

33 (showing 12, show less)
# Description HPO Frequency HPO Source Accession
1 seizures 33 frequent (33%) HP:0001250
2 eeg abnormality 33 frequent (33%) HP:0002353
3 increased serum serotonin 33 frequent (33%) HP:0003144
4 intellectual disability 33 HP:0001249
5 delayed speech and language development 33 HP:0000750
6 stereotypy 33 HP:0000733
7 autism 33 HP:0000717
8 impaired use of nonverbal behaviors 33 HP:0000758
9 restrictive behavior 33 HP:0000723
10 lack of peer relationships 33 HP:0002332
11 lack of spontaneous play 33 HP:0000721
12 inflexible adherence to routines or rituals 33 HP:0000732

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
lack of peer relationships
mental retardation in 75%
seizures in 15-30%
eeg abnormalities in 20-50%
impaired use of nonverbal behaviors, such as eye-to-eye gaze, facial expression, body posture, and gestures
more
Laboratory Abnormalities:
increased serum serotonin in 25%

Clinical features from OMIM:

300495

Drugs & Therapeutics for Autism X-Linked 2

Drugs for Autism X-Linked 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 236, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lovastatin Approved, Investigational Phase 4,Phase 2 75330-75-5 53232
2
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 62-31-7, 51-61-6 681
4
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
5
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
9 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Protective Agents Phase 4,Phase 3,Phase 2
11 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
12 Lipid Regulating Agents Phase 4,Phase 2,Not Applicable
13 L 647318 Phase 4,Phase 2
14 Antimetabolites Phase 4,Phase 2,Phase 1,Not Applicable
15 Anticholesteremic Agents Phase 4,Phase 2
16 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2
17 Dihydromevinolin Phase 4,Phase 2
18 Hypolipidemic Agents Phase 4,Phase 2,Not Applicable
19 Neuroprotective Agents Phase 4,Phase 2
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
21 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
22 Serotonin Antagonists Phase 4,Phase 3,Phase 2
23 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
29 Dopamine Uptake Inhibitors Phase 4
30 Central Nervous System Stimulants Phase 4
31
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
32
Tocopherol Approved, Investigational Phase 3,Phase 2 1406-66-2 14986
33
Ethanol Approved Phase 3,Phase 2 64-17-5 702
34 Strawberry Approved Phase 3,Phase 2
35
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
36
Donepezil Approved Phase 3,Phase 2,Phase 1,Not Applicable 120014-06-4 3152
37
Dextromethorphan Approved Phase 3,Phase 2,Not Applicable 125-71-3 5362449 5360696
38
Baclofen Approved Phase 3,Phase 2 1134-47-0 2284
39
Stiripentol Approved Phase 3 49763-96-4
40
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
41
tannic acid Approved Phase 3,Phase 2 1401-55-4
42
Acamprosate Approved, Investigational Phase 3,Phase 2 77337-76-9 71158
43
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
44
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
45
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3 50-18-0, 6055-19-2 2907
46
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
47
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 55-98-1 2478
48
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
49
Copper Approved, Investigational Phase 3,Phase 1,Phase 2 7440-50-8 27099
50
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
51
Fludarabine Approved Phase 3,Phase 1,Phase 2 75607-67-9, 21679-14-1 30751
52
Glycerol Approved, Investigational Phase 2, Phase 3 56-81-5 753
53
Clobazam Approved, Illicit Phase 3 22316-47-8 2789
54
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-02-9 14985
55
Vitamin C Approved, Nutraceutical Phase 3,Phase 2 50-81-7 54670067 5785
56
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1 56-86-0 33032
57
Biotin Approved, Investigational, Nutraceutical Phase 2, Phase 3 58-85-5 171548
58
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
59
Histidine Approved, Nutraceutical Phase 3,Phase 1,Phase 2 71-00-1 6274
60
Beta carotene Approved, Nutraceutical Phase 3 7235-40-7
61 Tocotrienol Investigational Phase 3,Phase 2 6829-55-6
62
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
63 Ecopipam Investigational Phase 3,Phase 1 112108-01-7
64 Vitamins Phase 3,Phase 2,Phase 1
65 Tocopherols Phase 3,Phase 2
66 Antioxidants Phase 3,Phase 2
67 Micronutrients Phase 3,Phase 2,Phase 1
68 Nutrients Phase 3,Phase 2,Phase 1
69 Trace Elements Phase 3,Phase 2,Phase 1
70 Tocotrienols Phase 3,Phase 2
71 Epidiolex Phase 3,Phase 2,Phase 1
72 Chlorpheniramine, phenylpropanolamine drug combination Phase 3,Phase 2,Not Applicable
73 Cholinesterase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
74 Antitussive Agents Phase 3,Phase 2,Not Applicable
75 Respiratory System Agents Phase 3,Phase 2,Not Applicable
76 Nootropic Agents Phase 3,Phase 2,Phase 1,Not Applicable
77 Cholinergic Agents Phase 3,Phase 2,Phase 1,Not Applicable
78 Immunologic Factors Phase 2, Phase 3,Phase 1,Not Applicable
79 Immunosuppressive Agents Phase 2, Phase 3,Phase 1,Not Applicable
80 Antirheumatic Agents Phase 2, Phase 3,Phase 1
81 Hormones Phase 2, Phase 3,Phase 1,Not Applicable
82 Vitamin B7 Phase 2, Phase 3
83 Vitamin B Complex Phase 2, Phase 3
84 Vitamin B9 Phase 2, Phase 3
85 Folate Phase 2, Phase 3
86 Serotonin Uptake Inhibitors Phase 3,Phase 2,Phase 1
87 Prednisolone acetate Phase 2, Phase 3
88 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1
89 Methylprednisolone Acetate Phase 2, Phase 3
90 Alkylating Agents Phase 2, Phase 3,Phase 1
91 Antilymphocyte Serum Phase 2, Phase 3,Phase 1
92 Cholic Acids Phase 3,Not Applicable
93 Gastrointestinal Agents Phase 3,Not Applicable
94 Bile Acids and Salts Phase 3,Not Applicable
95 Liver Extracts Phase 3
96 Hypoglycemic Agents Phase 2, Phase 3,Not Applicable
97 Hormone Antagonists Phase 2, Phase 3
98 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
99 pyruvate Phase 3,Phase 1,Phase 2
100 GABA Agents Phase 3,Phase 2
101 GABA Agonists Phase 3,Phase 2
102 Carotenoids Phase 3
103 GABA-A Receptor Agonists Phase 3
104 Anti-Anxiety Agents Phase 3
105
Pseudoephedrine Approved Phase 2 90-82-4 7028
106
Ephedrine Approved Phase 2 299-42-3 9294
107
Minocycline Approved, Investigational Phase 2,Not Applicable 10118-90-8 5281021
108
Zinc Approved, Investigational Phase 2,Phase 1 7440-66-6 32051
109
Mecasermin Approved, Investigational Phase 2,Phase 1 68562-41-4
110
Sertraline Approved Phase 2 79617-96-2 68617
111
Oxytocin Approved, Vet_approved Phase 2 50-56-6 53477758 439302
112
Desipramine Approved, Investigational Phase 2 50-47-5 2995
113
Aripiprazole Approved, Investigational Phase 2 129722-12-9 60795
114
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
115
Adalimumab Approved Phase 1, Phase 2,Phase 2 331731-18-1 16219006
116
Verapamil Approved Phase 2 52-53-9 2520
117
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
118
Mycophenolic acid Approved Phase 2 24280-93-1 446541
119
alemtuzumab Approved, Investigational Phase 2 216503-57-0
120
Mesna Approved, Investigational Phase 2 3375-50-6 598
121
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
122
Hydroxyurea Approved Phase 2 127-07-1 3657
123
Melphalan Approved Phase 2 148-82-3 460612 4053
124
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
125
Ketamine Approved, Vet_approved Phase 2,Phase 1 6740-88-1 3821
126
Thiotepa Approved, Investigational Phase 1, Phase 2,Phase 2 52-24-4 5453
127
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
128
rituximab Approved Phase 2 174722-31-7 10201696
129
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
130
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
131
Calcium Approved, Nutraceutical Phase 2,Phase 1 7440-70-2 271
132
Epigallocatechin gallate Investigational Phase 2,Not Applicable 989-51-5 65064
133
Epigallocatechin Experimental, Investigational Phase 2,Not Applicable 970-74-1 72277
134
Gaboxadol Investigational Phase 2,Phase 1 64603-91-4 3448
135 Adjuvants, Immunologic Phase 2,Phase 1
136 (T,G)-A-L Phase 2,Phase 1
137
Glatiramer Acetate Phase 2,Phase 1 147245-92-9 3081884
138 Mitogens Phase 2,Not Applicable
139 Adrenergic alpha-Agonists Phase 2
140 Appetite Depressants Phase 2
141 Peripheral Nervous System Agents Phase 2,Phase 1
142 Anti-Obesity Agents Phase 2
143 Nasal Decongestants Phase 2
144 Expectorants Phase 2
145 Adrenergic Agonists Phase 2
146 Adrenergic Agents Phase 2
147 Sympathomimetics Phase 2
148
Chlorpheniramine Phase 2 113-92-8, 132-22-9 2725
149 Vasoconstrictor Agents Phase 2
150 Autonomic Agents Phase 2
151 Anti-Bacterial Agents Phase 2,Not Applicable
152 Anti-Infective Agents Phase 2,Not Applicable
153 Metadoxine Phase 2
154 Vitamin B 6 Phase 2
155 Fingolimod Hydrochloride Phase 1, Phase 2
156 Estrogens Phase 2
157 Tea Phase 2,Not Applicable
158 Ubiquinone Phase 2
159 insulin Phase 2,Phase 1
160 Insulin, Globin Zinc Phase 2,Phase 1
161 Pregnanolone Phase 2 128-20-1
162 Anesthetics Phase 2,Phase 1
163 Antidepressive Agents Phase 2
164 Oxytocics Phase 2
165 Antidepressive Agents, Tricyclic Phase 2
166 Dopamine agonists Phase 2
167 Serotonin 5-HT1 Receptor Agonists Phase 2
168 Serotonin Receptor Agonists Phase 2
169 Dopamine D2 Receptor Antagonists Phase 2
170 Serotonin 5-HT2 Receptor Antagonists Phase 2
171 Anti-Inflammatory Agents Phase 1, Phase 2,Phase 2
172 Anti-Arrhythmia Agents Phase 2
173 Vasodilator Agents Phase 2
174 calcium channel blockers Phase 2
175 Calcium, Dietary Phase 2,Phase 1
176 Free Radical Scavengers Phase 2
177 Antidotes Phase 2
178 Antiviral Agents Phase 2,Not Applicable
179 Thioctic Acid Phase 2
180 N-monoacetylcystine Phase 2
181 Alpha-lipoic Acid Phase 2
182 Dermatologic Agents Phase 2
183 Antitubercular Agents Phase 2
184 Cyclosporins Phase 2
185 Antineoplastic Agents, Immunological Phase 2
186 Antifungal Agents Phase 2
187 Antibiotics, Antitubercular Phase 2
188 Calcineurin Inhibitors Phase 2
189 Antimetabolites, Antineoplastic Phase 2,Phase 1
190 Nucleic Acid Synthesis Inhibitors Phase 2
191 Analgesics Phase 2,Phase 1
192 Anesthetics, Intravenous Phase 2,Phase 1
193 Anesthetics, Dissociative Phase 2,Phase 1
194 Anesthetics, General Phase 2,Phase 1
195 Phosphodiesterase 4 Inhibitors Phase 2
196 4-phenylbutyric acid Phase 1, Phase 2
197 Thymoglobulin Phase 1, Phase 2,Phase 2
198
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
199
Vitamin D3 Approved, Nutraceutical Phase 1 67-97-0 5280795 6221